798-P: Potential Cardioprotective Effects of HM15275, a Novel, Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Hypertension

Introduction p0.001). In line with these results, both interstitial and perivascular fibrosis (% of extracellular collagen area using MT staining) were significantly improved by HM15275 treatment (-52.8% vs. TZP; p0.001). In Ang II mice, the levels of pro-collagen-1α1 were significantly decreased by HM15275 in the heart (-40.5% vs. TZP; p0.001). Moreover, cardiomyocyte enlargement caused by Ang II was significantly reduced by HM15275 treatment for 2 weeks. Similar benefits were also confirmed in AMLN mice. Conclusion: Collectively, the results showed that HM15275 could have more potent cardioprotective effects than TZP in hypertension mediated cardiac damage. Further mechanistic studies are needed to elucidate the MoA for the beneficial effects of HM15275. Disclosure S. Lee: None. J. Kim: None. E. Park: None. H. Kang: None. J.A. Kim: None. Y. Kim: None. S. Hong: None. S. Bae: None. S. Lee: None. I. Choi: None.